Holen Sie sich die Stockscreener-App
273.09
1.57%
-4.3477
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$277.44
Offen:
$275.64
24-Stunden-Volumen:
898.08K
Relative Volume:
1.03
Marktkapitalisierung:
$39.98B
Einnahmen:
$5.02B
Nettoeinkommen (Verlust:
$1.31B
KGV:
30.65
EPS:
8.91
Netto-Cashflow:
$1.56B
1W Leistung:
-0.15%
1M Leistung:
+5.84%
6M Leistung:
+15.62%
1J Leistung:
+28.06%
1-Tages-Spanne:
$272.63
$277.30
1-Wochen-Bereich:
$270.87
$278.86
52-Wochen-Spanne:
$199.92
$278.86
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
272.69 | 40.72B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
482.59 | 178.12B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
179.08 | 52.27B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.41 | 45.23B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
238.52 | 18.19B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
RMD ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ResMed Inc. - ACCESS Newswire
When is ResMed Inc. stock expected to show significant growthFree Stock Data Feed Backed By Experts - jammulinksnews.com
ResMed's 257th High-Volume Rank and Earnings Outlook Signal Strategic Short-Term Opportunities - AInvest
Spot Outliers Like ResMed Early with Money Flows - FXEmpire
ResMed Earnings Preview: Anticipating Growth Amidst Industry TrendsNews and Statistics - IndexBox
Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares? - The Motley Fool Australia
Will ResMed Inc. stock benefit from interest rate changesDay Trading Signals With High Precision Reviewed - metal.it
ResMed (RMD) To Report Earnings Tomorrow: Here Is What To Expect - TradingView
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD) - Yahoo.co
ResMed stock hits 52-week high at 275.86 USD By Investing.com - Investing.com Canada
ResMed stock hits 52-week high at 275.86 USD - Investing.com
ResMed Inc. Stock Poised for Technical ComebackTrade Scanner With Buy Zone Alerts Flagged - metal.it
How does ResMed Inc. compare to its industry peersBuild a diversified portfolio for risk management - jammulinksnews.com
What catalysts could drive ResMed Inc. stock higher in 2025Get exclusive market analysis for investors - jammulinksnews.com
What are analysts’ price targets for ResMed Inc. in the next 12 monthsPre Market Forecasts That Work - jammulinksnews.com
What is the dividend policy of ResMed Inc. stockRecord-breaking capital gains - jammulinksnews.com
Why ResMed Inc. stock attracts strong analyst attentionBig Profit Small Risk Alerts - metal.it
What makes ResMed Inc. stock price move sharplyAccess powerful market insights for free - jammulinksnews.com
Why is ResMed Inc. stock attracting strong analyst attentionTrack emerging stocks with high growth potential - jammulinksnews.com
Are Resmed CDI (ASX:RMD) shares good value in 2025? - Rask Media
Are Robust Financials Driving The Recent Rally In ResMed Inc.'s (NYSE:RMD) Stock? - 富途牛牛
What makes ResMed Inc. stock attractive to long term investorsVolume Spike Monitors - metal.it
Fisher & Paykel Healthcare (FPH AU) Vs. ResMed (RMD AU): Dislocation in Healthcare - Smartkarma
If You Invested $1000 in ResMed a Decade Ago, This is How Much It'd Be Worth Now - MSN
What drives ResMed Inc. stock priceFree Stock Selection - PrintWeekIndia
What analysts say about ResMed Inc. stockTremendous return on equity - PrintWeekIndia
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
ResMed Inc. Fiscal Q4 2025 Earnings Announcement and Market OutlookNews and Statistics - IndexBox
Here's What To Expect From ResMed's Next Earnings Report - Barchart.com
ResMed (RMD) Offers Hope with Apnimed's Positive Phase 3 Trial R - GuruFocus
MIN and Resmed CDI: 2 ASX shares to dig into - Rask Media
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
ResMed Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
Is ResMed Inc. a good long term investmentMarket-beating returns - jammulinksnews.com
ResMed stock hits 52-week high at 263.62 USD - Investing.com Australia
ResMed stock hits 52-week high at 263.62 USD By Investing.com - Investing.com Nigeria
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research® - GlobeNewswire Inc.
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
3.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):